COMMENTARY

• Final Decision on Avastin's Indication for Breast Cancer Must Satisfy the Public
  August 29, 2011

• Why Eisai's Novel Anticancer Agent Halaven Received the Highest Ever Operating Profit Rate
  August 8, 2011

• Current Promising Drug Candidates with a New Mode of Action
  August 8, 2011

• Consumption Tax Hike to Go With Measures to Increase Efficiency of Soc. Security System
  July 18, 2011

• Actos Bladder Cancer Risk Highlights Problems with Safety Measures in Japan
  July 4, 2011

• Era of Competition Dawns in Market for AD Treatments
  June 27, 2011

• Will Dialogue between PSJ, JAMS Accelerate Development of Switch OTC Drugs?
  June 20, 2011

• Return to Full-bore Growth Strategy Risky for Taiyo Pharm
  June 13, 2011

• Why the Same Mistake Repeated? -MSD's Promotion Code Violations
  June 6, 2011

• GE Makers to Make Difficult Decision on Actos Generics due to Combination Patent
  June 6, 2011

• Effects of Changes to Accelerate Approval to Be Seen from November
  May 30, 2011

• Japan's Most Admired Pharma Companies in 2010
  April 4, 2011

• Will New Disclosure GL Promote Industry-Academia Alliances?
  March 28, 2011

• Use of Generics by Welfare Recipients
  March 7, 2011

• Wholesalers' Profits Drop Sharply Putting Premium for New Drug Development in Peril
  February 21, 2011

• Safety Measures Based on Common Medical Knowledge Questioned by Court: Iressa Affair
  February 21, 2011

• Recent Topics in Promising Anticancer Therapeutics
  January 17, 2011

• Development Race for Oral Anticoagulants Entering Final Stretch
  October 11, 2010

• How to Eliminate Concerns about Safety of Liovel
  October 4, 2010

• Will It Be Possible to Eliminate Unnecessary Equivalence Studies for Generics?
  September 20, 2010

ページ